Researchers studied why obesity raises blood pressure and focused on beige fat. They removed the gene Prdm16 only in fat cells of mice so the animals did not become obese or inflamed. This let them test beige fat alone.
When beige identity was lost, fat around blood vessels looked like white fat and made angiotensinogen, a precursor to a hormone that raises blood pressure. The engineered mice developed higher blood pressure and stiffer vessels. The team found a protein called QSOX1 in the altered fat. Mice without both Prdm16 and Qsox1 did not get the vessel problems. Doctors also saw higher blood pressure in people with PRDM16 mutations.
Difficult words
- obesity — a condition of having too much body fat
- gene — a small part of DNA that controls traits
- beige — a kind of body fat with special cellsbeige fat, beige identity
- precursor — a substance that comes before another
- inflamed — red, swollen and often painful from injury
- stiffer — less flexible and more hard to bend
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why did the researchers remove Prdm16 only in fat cells?
- How might higher blood pressure change a person’s daily life?
Related articles
Yale reveals molecular structure of cholera flagella
Yale researchers imaged the molecular structure of Vibrio cholerae flagella in living bacteria. The study shows how flagella proteins sit inside a hydrophilic sheath and suggests the sheath helps the bacterium move and infect cells.
Cholera spreads where water and health systems fail
Cholera spread widely in 2024, with 560,823 reported cases and 6,028 deaths. Conflict, climate shocks and damaged water and health services drove outbreaks, while vaccines and better water and sanitation are key to preventing deaths.
Personalized DNA vaccine shows promise against glioblastoma
A phase 1 trial found the personalized DNA vaccine GNOS-PV01 is safe and shows early signs of activity against glioblastoma. The small study at Siteman Cancer Center and WashU Medicine reported immune responses and encouraging clinical outcomes.